News >

Olaparib Takes Key Regulatory Step Toward Japanese Approval in Pancreatic Cancer

Jason M. Broderick @jasoncology
Published: Thursday, Mar 19, 2020

Jose Baselga, MD, PhD, executive vice president, Oncology R&D, AstraZenec

José Baselga, MD, PhD

Olaparib (Lynparza) has received an orphan drug designation in Japan for the maintenance treatment of germline BRCA-mutated curatively unresectable pancreatic cancer, according to AstraZeneca and Merck (MSD), the codevelopers of the PARP inhibitor.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication